Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × trastuzumab deruxtecan × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 1 Solid Cancer 1 Recurrence 1 Neoplasm, Residual 1 HER2-mutant Non-Small Cell Lung Cancer 1 HER2-Positive Primary Breast Cancer 1 Adenocarcinoma 1

Interventions

Cyclophosphamide 18 Dexamethasone 17 fludarabine 11 pomalidomide 8 carfilzomib 7 Rituximab 7 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 Lenalidomide 6 Calcium Dobesilate 6 venetoclax 5 Gemcitabine 5 Cisplatin 5 Bortezomib 5 Nivolumab 4 Etoposide 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cemiplimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05704829 2025-11-19

ADAPTHER2-IV

West German Study Group

Phase 2 Active not recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡